Medtronic Enters Leadless Pacemaker Competition With Micra CE Mark
This article was originally published in The Gray Sheet
Executive Summary
The firm’s ultra-small leadless pacing system has been cleared to launch in Europe, where it will face off with St. Jude’s Nanostim, which is slowly recovering from a pause in implants in 2014.
You may also be interested in...
Medtronic Goes Small With Leadless Pacer, Cardiac Monitor
The firm announced the first U.S. implant for its investigational Micra transcatheter, leadless pacing system, and the global launch of its miniature Reveal LINQ implantable cardiac monitor.
St. Jude First To Market Leadless Pacemaker With Nanostim Buy
St. Jude paid $123.5 million and agreed to up to $65 million in additional milestone payments to acquire Nanostim and its first-in-class leadless pacemaker, which has just earned a CE mark and is expected to launch in select European markets soon.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.